<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119442</url>
  </required_header>
  <id_info>
    <org_study_id>13-001008</org_study_id>
    <nct_id>NCT02119442</nct_id>
  </id_info>
  <brief_title>Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves</brief_title>
  <official_title>Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing body of data, suggests that transcatheter valves are effective when implanted in
      other locations (mitral, aortic, tricuspid) and in high pressure environments. The
      investigators plan to offer transcatheter valve implantation as an alternative to high risk
      surgery in patients who require revision of a stenotic or regurgitant valve in the
      non-pulmonary position (mitral, aortic, tricuspid). This therapy can provide an alternative
      to patients who may be considered high risk and may not be able to survive a surgical
      procedure.The use of the devices on this protocol are for medical treatment and are not part
      of a clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many forms of congenital and structural heart disease require surgical placement of
      prosthetic valves and conduits. These conditions include many common congenital heart
      abnormalities such as Tetralogy of Fallot, Double Outlet Right Ventricle, Truncus Arteriosus
      and patients who require the Ross procedure for aortic stenosis. There are a variety of
      acquired conditions, including calcific aortic valve stenosis that may require surgical or
      transcatheter valve treatment. Unfortunately, when valved conduits are placed surgically,
      they ultimately become narrowed or regurgitant and require periodic replacement. Thus,
      patients with these conditions often undergo multiple open heart surgeries during their
      lifetime. Although the risk of mortality with this kind of surgery is low, surgical
      intervention is associated with significantly longer recovery times and more patient
      discomfort when compared to transcatheter interventions. Over the last decade, techniques
      have been developed to palliate these forms of congenital and structural heart disease using
      catheters inserted through blood vessels in the groin. These transcatheter techniques have
      allowed patients to delay or avoid open heart surgery.

      The Medtronic Melody Trancatheter Valve and the Edwards SAPIEN Transcatheter Heart Valve are
      both bioprosthetic valves mounted within metal stents. Their entire structure is collapsible,
      allowing it to be inserted through delivery sheaths and threaded into the heart, typically
      without the need of surgical cardiopulmonary bypass. Some of these procedures may be
      performed using a hybrid technique of minimal surgical access and transcatheter valve
      delivery. The valves can then be expanded into place by inflating a balloon (similar to how
      stents are placed elsewhere in the heart, like the coronary artery). The Melody Valve
      received a humanitarian device exemption (HDE) from the FDA and the Edwards Sapien Valve has
      market approval from the FDA.The investigators plan to offer these transcatheter valves as
      alternatives to eligible patients who require replacement of a stenotic or regurgitant valve
      in all left and right sided positions.

      The intended role of the Melody Transcatheter Pulmonary Valve is to restore pulmonary valve
      function in patients with a dysfunctional RVOT conduit and a clinical indication for
      pulmonary valve replacement. Unlike currently available options for pulmonary valve
      replacement, the TPV is intended to be placed with a transcatheter delivery system, and thus
      does not require surgical incisions, open heart surgery, cardiopulmonary bypass, or the
      various morbidities associated with surgical pulmonary valve replacement. The Edwards Sapien
      Valve is delivered in the same manner, but was intended for use in the aortic position. The
      ultimate goals and durability of the TPV may differ among patients with different
      indications. At a minimum, the intention is that the TPV will improve hemodynamic function,
      mitigate the adverse impact of valve regurgitation and/or obstruction, and effectively extend
      the longevity of the existing conduit and defer or obviate the need for conduit replacement.
      These techniques may decrease the number of open heart surgeries required over the course of
      a patient's lifetime, thereby decreasing the cumulative morbidity and risk associated with
      such operations.

      With regards to valve replacement in any position with an adequate landing zone, the Melody
      Valve and Edwards Sapien Valve are presently being utilized at multiple United States centers
      for valve replacement in all positions in patients who are considered high risk candidates
      for surgical valve replacement. A recent article published by Zahn et al reported an
      experience in tricuspid valve implantations at three United States centers and one
      Austrailian center. Procedural success was achieved in all patients. Tricuspid regurgitation
      was reduced to mild or none in all patients. Noted complications were consistent with known
      risks of cardiac catheterization and Melody Valve implantation, regardless of indication.
      Similarly, an article published by Kenny et al demonstrated the successful implantation of
      the Sapien valve in the tricuspid position. Gillespie et al, recently published a series of
      Melody implants in the mitral position in sheep that had undergone annuloplasty ring
      placement. Other investigators have successfully implanted the Melody valve in the aortic and
      mitral positions in patients with good immediate and short/intermediate term outcomes
      (Ben-Gal et al, Hasan et al, Gossl et al). The Edwards Sapien Valve has several reports of
      positive outcomes when implanted within the aortic position (Thomas et al, Moat et al, Webb
      et al) and two case series that report encouraging results when placed in the mitral
      position. (Seiffert et al, Cheung et al)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Developed Infective Endocarditis</measure>
    <time_frame>8 years</time_frame>
    <description>The investigator will be assessing the efficacy of transcatheter heart valve (THV) by evaluating survival and development of infective endocarditis as an adverse event.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Eisenmenger Syndrome</condition>
  <arm_group>
    <arm_group_label>Transcatheter Valve Implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcather Valve Implantation</intervention_name>
    <description>Transcather Valve Implantation</description>
    <arm_group_label>Transcatheter Valve Implantation</arm_group_label>
    <other_name>Medtronic Melody Transcatheter Valve; Melody TPV 20 PB1016:Melody TPV 22 PB1018</other_name>
    <other_name>Edwards SAPIEN Transcatheter Heart Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be considered eligible for transcatheter valve implantation if the risk
             of serious morbidity or mortality with surgical intervention is deemed to be greater
             than 10 percent by the treating cardiologist and consulting surgeon. The Melody Valve
             is intended for use in the following clinical conditions:

          -  Existence of a full (circumferential) RVOT conduit that was equal to or greater than
             16 mm in diameter when originally implanted, AND

          -  Dysfunctional RVOT conduits with a clinical indication for intervention, AND EITHER

          -  Regurgitation ≥ moderate

          -  Stenosis: mean right ventricular outflow tract gradient ≥ 35 mmHg

          -  The Edwards Sapien Valve will be used in the aortic position for valves and conduits
             larger than 23mm in diameter with a landing zone less than 26-27mm, otherwise the
             melody valve will be considered

          -  The Edwards Sapien Vavle will also be considered in other positions that have an
             adequate landing zone and a large enough circumference

          -  The Melody valve may be utilized outside of its approved indications for valve
             replacement in high risk surgical patients

        Exclusion Criteria:

          -  There are no known contraindications for implantation of the Melody Valve or the
             Edwards Sapien Valve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamil A Aboulhosn, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kondo N, Shuto T, McGarvey JR, Koomalsingh KJ, Takebe M, Gorman RC, Gorman JH 3rd, Gillespie MJ. Melody valve-in-ring procedure for mitral valve replacement: feasibility in four annuloplasty types. Ann Thorac Surg. 2012 Mar;93(3):783-8. doi: 10.1016/j.athoracsur.2011.12.021.</citation>
    <PMID>22364973</PMID>
  </reference>
  <reference>
    <citation>Riede FT, Dähnert I. Implantation of a Melody valve in tricuspid position. Catheter Cardiovasc Interv. 2012 Sep 1;80(3):474-6. doi: 10.1002/ccd.23404. Epub 2012 Mar 14.</citation>
    <PMID>22105855</PMID>
  </reference>
  <reference>
    <citation>Ben-Gal Y, Finkelstein A, Bruckheimer E, Banai S, Keren G, Kramer A, Uretzky G. Transapical implantation of a Melody valve in a degenerated low-diameter prosthetic aortic valve. Circulation. 2013 Apr 23;127(16):e553-6. doi: 10.1161/CIRCULATIONAHA.112.127027.</citation>
    <PMID>23609553</PMID>
  </reference>
  <reference>
    <citation>Cheung AW, Gurvitch R, Ye J, Wood D, Lichtenstein SV, Thompson C, Webb JG. Transcatheter transapical mitral valve-in-valve implantations for a failed bioprosthesis: a case series. J Thorac Cardiovasc Surg. 2011 Mar;141(3):711-5. doi: 10.1016/j.jtcvs.2010.11.026. Epub 2011 Jan 26.</citation>
    <PMID>21269643</PMID>
  </reference>
  <reference>
    <citation>Kenny D, Hijazi ZM, Walsh KP. Transcatheter tricuspid valve replacement with the Edwards SAPIEN valve. Catheter Cardiovasc Interv. 2011 Aug 1;78(2):267-70. doi: 10.1002/ccd.23016. Epub 2011 Jul 15.</citation>
    <PMID>21766424</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>April 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jamil Aboulhosn</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Eisenmenger Syndrome, Pulmonary Arterial Hyptertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eisenmenger Complex</mesh_term>
    <mesh_term>Dextrocardia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02119442/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02119442/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transcatheter Valve Implantation</title>
          <description>Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention. All participants were considered to be under the same Arm/Group.
Transcather Valve Implantation: Transcather Valve Implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transcatheter Valve Implantation</title>
          <description>Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
Transcather Valve Implantation: Transcather Valve Implantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="3" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Infective Endocarditis</title>
        <description>The investigator will be assessing the efficacy of transcatheter heart valve (THV) by evaluating survival and development of infective endocarditis as an adverse event.</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcatheter Valve Implantation</title>
            <description>Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
Transcather Valve Implantation: Transcather Valve Implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Infective Endocarditis</title>
          <description>The investigator will be assessing the efficacy of transcatheter heart valve (THV) by evaluating survival and development of infective endocarditis as an adverse event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected until the latest follow up time point that the patients were seen by a physician. This time point included at least one year of follow up or more.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transcatheter Valve Implantation</title>
          <description>Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
Transcather Valve Implantation: Transcather Valve Implantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>infective endocarditis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Soraya Sadeghi</name_or_title>
      <organization>UCLA</organization>
      <phone>3108255950</phone>
      <email>smsadeghi@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

